The Relationship Between Quality of Life, Anxiety Levels, and Attitudes Toward Artificial Intelligence Among Women Undergoing Infertility Treatment

December 17, 2025 updated by: Güzin Ünlü Suvari, Acibadem University
Infertility affects approximately one in six individuals worldwide and is associated with significant psychological distress, particularly among women undergoing treatment. Increased anxiety levels are strongly linked to reduced quality of life during the infertility process. With the growing integration of artificial intelligence (AI) into healthcare, AI-based tools are increasingly used in infertility care to support decision-making and patient engagement. While many patients are familiar with AI technologies, individual attitudes toward AI may influence their acceptance and potential psychosocial benefits. This study aims to examine the relationship between attitudes toward artificial intelligence, anxiety levels, and quality of life among women undergoing infertility treatment.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

191

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey (Türkiye)
    • Ataşehir
      • Istanbul, Ataşehir, Turkey (Türkiye)
        • Recruiting
        • Acıbadem Health Group
        • Contact:
        • Principal Investigator:
          • Merve Coşkun, Ph.D.
        • Principal Investigator:
          • Ergül Aslan, Prof.
        • Principal Investigator:
          • Hale Göksever Çelik, Prof. Dr.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Women aged 18-45 years diagnosed with primary or secondary infertility and currently undergoing infertility treatment (IUI, IVF, or ICSI).

Description

Inclusion Criteria:

  • Women aged 18-45 years diagnosed with infertility (primary or secondary infertility).
  • Women undergoing infertility treatment and those who have experienced various treatment modalities (IUI, IVF, ICSI).
  • Women who voluntarily agree to participate in the study.
  • Women who are able to understand and speak Turkish.

Exclusion Criteria:

  • Women with diagnosed psychological disorders (e.g., clinical depression, anxiety disorders).
  • Women who are not undergoing infertility treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sociodemographic and Descriptive Information Form
Time Frame: At baseline (one-time assessment at enrollment)
This form includes 30 items designed to collect data on participants' sociodemographic characteristics, general health status, obstetric and gynecological history, and use of technology and artificial intelligence. It provides a comprehensive background profile of women undergoing infertility treatment.
At baseline (one-time assessment at enrollment)
State-Trait Anxiety Inventory (STAI) - Trait Anxiety Scale
Time Frame: At baseline (one-time assessment at enrollment)
The Trait Anxiety Scale is used to assess individuals' general and persistent anxiety levels. The scale consists of multiple items rated on a Likert-type format, with total scores ranging from 20 to 80. Higher scores indicate higher levels of anxiety.
At baseline (one-time assessment at enrollment)
General Attitudes Toward Artificial Intelligence Scale
Time Frame: At baseline (one-time assessment at enrollment)
This scale assesses individuals' positive and negative attitudes toward artificial intelligence using a 5-point Likert-type format. It consists of 20 items, with negatively worded items reverse-coded. Higher total scores reflect more positive attitudes toward artificial intelligence.
At baseline (one-time assessment at enrollment)
Fertility Quality of Life Scale (FertiQol) - Core Module
Time Frame: At baseline (one-time assessment at enrollment)
The Fertility Quality of Life Scale evaluates quality of life in individuals experiencing fertility problems. The core module assesses emotional, mind-body, relational, and social dimensions of quality of life using a Likert-type response format. Higher scores indicate better quality of life.
At baseline (one-time assessment at enrollment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Acibadem University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 23, 2025

Primary Completion (Estimated)

October 23, 2026

Study Completion (Estimated)

October 23, 2026

Study Registration Dates

First Submitted

December 17, 2025

First Submitted That Met QC Criteria

December 17, 2025

First Posted (Actual)

December 29, 2025

Study Record Updates

Last Update Posted (Actual)

December 29, 2025

Last Update Submitted That Met QC Criteria

December 17, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-15/591

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be publicly shared due to privacy concerns and the sensitive nature of maternal and infant health information. However, anonymized data may be made available upon reasonable request to the corresponding author after publication of the study results.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe